LENSAR (NASDAQ:LNSR) Announces Earnings Results, Misses Estimates By $0.28 EPS

Key Points

• LENSAR reported a quarterly loss of $0.38 per share, missing the consensus estimate of a $0.10 loss by $0.28. Revenue was $14.13 million, slightly below the $14.30 million expected.
• Recurring revenue rose 17% to $12.6 million, procedure volume grew 12%, and gross margin improved to 58% from 42%. Adjusted EBITDA was positive at $1.7 million, though the GAAP net loss widened to $4.7 million, largely due to a non-cash warrant-liability expense.
• Management expects $1 million–$2 million in cash burn for the rest of 2026 and sees moving closer to break-even in 2027. Overseas activity is recovering gradually, while executives noted recent softness in U.S. cataract procedure volumes.

LENSAR (NASDAQ:LNSR - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.28), FiscalAI reports. The business had revenue of $14.13 million for the quarter, compared to analysts' expectations of $14.30 million. LENSAR had a net margin of 57.57% and a negative return on equity of 529.08%.

Here are the key takeaways from LENSAR's conference call:

• Recurring revenue rose 17% to $12.6 million, procedure revenue increased 17%, and procedure volume grew 12% year over year. Recurring revenue made up 89% of total revenue, helping offset a 1% decline in total revenue as system sales fell against a strong prior-year comparison.
• LENSAR placed 10 ALLY systems, bringing its installed base to approximately 225, while market share edged up to 24.5%. The company said new robotic docking features are expected around the end of Q1 2027, potentially supporting further adoption.
• Gross margin improved to 58% from 42%, operating loss narrowed to about $1.4 million, and adjusted EBITDA turned positive at $1.7 million. GAAP net loss widened to $4.7 million, largely due to a non-cash warrant-liability expense.
• Management described overseas commercial activity as still recovering after distributor disruption, seasonal holidays, and reimbursement changes, and expects a gradual ramp into 2027. Executives also noted that U.S. cataract procedure volumes have recently been slightly softer.
• Cash and investments were $12.6 million at quarter-end, supplemented by a new $10 million revolving credit line. Management anticipates $1 million–$2 million of cash burn for the rest of 2026 and said it expects to move closer to break-even at some point in 2027.

LENSAR Stock Performance

Shares of NASDAQ LNSR traded down $0.64 during midday trading on Tuesday, hitting $4.83. 114,054 shares of the company traded hands, compared to its average volume of 90,033. LENSAR has a 12-month low of $4.62 and a 12-month high of $12.94. The firm has a market cap of $59.30 million, a P/E ratio of -14.62 and a beta of 1.03. The stock has a 50-day moving average price of $6.73 and a 200 day moving average price of $7.32.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Loop Capital set a $11.00 price objective on LENSAR in a research report on Monday, September 28th. Lake Street Capital reissued a "buy" rating and set a $13.00 target price on shares of LENSAR in a research note on Thursday, August 13th. Wall Street Zen downgraded LENSAR from a "buy" rating to a "hold" rating in a report on Saturday, October 3rd. BTIG Research dropped their price target on LENSAR from $10.00 to $9.00 and set a "buy" rating for the company in a research note on Tuesday. Finally, Weiss Ratings upgraded shares of LENSAR from a "sell (d)" rating to a "sell (d+)" rating in a report on Thursday, October 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, LENSAR presently has an average rating of "Hold" and a consensus target price of $11.00.

LENSAR Company Profile

LENSAR, Inc is a medical technology company focused on ophthalmic laser systems used in cataract surgery and other procedures involving the eye. The company develops and commercializes femtosecond laser technology designed to assist surgeons with key steps of cataract surgery, including corneal incisions, capsulotomy and lens fragmentation.

Its product portfolio includes the LENSAR Laser System, which incorporates image-guidance and planning technologies intended to support precise, customized procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.